AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference
LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 22–26, 2021.
During a fireside chat, AC Immune CEO Prof. Andrea Pfeifer will discuss the Company’s execution strategy to advance and accelerate its precision medicine approach to targeting neurodegenerative diseases. Prof. Pfeifer will also highlight AC Immune’s novel anti-phospho-Tau (pTau) vaccine candidate ACI-35.030, including recent that showed promising immunogenicity and safety in patients with early Alzheimer’s disease. AC Immune is developing ACI-35.030 in collaboration with its strategic partner Janssen Pharmaceuticals, Inc.
SVB Leerink 10th Annual Global Healthcare Conference
Date: February 24, 2020 | 11:20–11:50 am ET / 5:20–5:50 pm CET
Format: Fireside chat
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA
A webcast of the fireside chat will be available on the of AC Immune’s website.
About AC Immune SA
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.
For further information, please contact:
| Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: Email: | US Media Katie Gallagher LaVoie Health Science Phone: Email: |
| European Investors & Media Chris Maggos LifeSci Advisors Phone: Email: |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of COVID-19 on our business, suppliers, patients and employees and any other impact of COVID-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
